Please use this identifier to cite or link to this item: doi:10.22028/D291-32084
Title: The iRhom2/ADAM17 Axis Attenuates Bacterial Uptake by Phagocytes in a Cell Autonomous Manner
Author(s): Seifert, Anke
Wozniak, Justyna
Düsterhöft, Stefan
Kasparek, Petr
Sedlacek, Radislav
Dreschers, Stephan
Orlikowsky, Thorsten W.
Yildiz, Daniela
Ludwig, Andreas
Language: English
Title: International Journal of Molecular Sciences
Volume: 21
Issue: 17
Publisher/Platform: MDPI
Year of Publication: 2020
Free key words: metalloproteinase
ADAM17
iRhom2
bacterial phagocytosis
inflammation
infection
shedding
chemokines
phagocytes
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Uptake of bacteria by phagocytes is a crucial step in innate immune defence. Members of the disintegrin and metalloproteinase (ADAM) family critically control the immune response by limited proteolysis of surface expressed mediator molecules. Here, we investigated the significance of ADAM17 and its regulatory adapter molecule iRhom2 for bacterial uptake by phagocytes. Inhibition of metalloproteinase activity led to increased phagocytosis of pHrodo labelled Gram-negative and -positive bacteria (E. coli and S. aureus, respectively) by human and murine monocytic cell lines or primary phagocytes. Bone marrow-derived macrophages showed enhanced uptake of heat-inactivated and living E. coli when they lacked either ADAM17 or iRhom2 but not upon ADAM10-deficiency. In monocytic THP-1 cells, corresponding short hairpin RNA (shRNA)-mediated knockdown confirmed that ADAM17, but not ADAM10, promoted phagocytosis of E. coli. The augmented bacterial uptake occurred in a cell autonomous manner and was accompanied by increased release of the chemokine CXCL8, less TNFα release and only minimal changes in the surface expression of the receptors TNFR1, TLR6 and CD36. Inhibition experiments indicated that the enhanced bacterial phagocytosis after ADAM17 knockdown was partially dependent on TNFα-activity but not on CXCL8. This novel role of ADAM17 in bacterial uptake needs to be considered in the development of ADAM17 inhibitors as therapeutics.
DOI of the first publication: 10.3390/ijms21175978
Link to this record: urn:nbn:de:bsz:291--ds-320841
hdl:20.500.11880/30423
http://dx.doi.org/10.22028/D291-32084
ISSN: 1422-0067
Date of registration: 25-Jan-2021
Description of the related object: Supplementary Materials
Related object: http://www.mdpi.com/1422-0067/21/17/5978/s1
Faculty: M - Medizinische Fakultät
ZE - Zentrale Einrichtungen
Department: M - Experimentelle und Klinische Pharmakologie und Toxikologie
ZE - Zentrum für Human- und Molekularbiologie (ZHMB)
Professorship: M - Jun.-Prof. Dr. Daniela Yildiz
ZE - Sonstige
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
ijms-21-05978-v2.pdf2,69 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons